https://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Ironwood-Reports-Positive-Top-Line-Data-from-Exploratory-Phase-IIa-Trial-Of-IW-3718-in-Refractory-Gastroesophageal-Reflux-Disease/default.aspx
Ironwood Pharmaceuticals is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients.
- February 4, 2015